The U.S. Food and Drug Administration issued warning letters to Eli Lilly, Novo Nordisk and telehealth firm Hims & Hers ...

Misleading promotions of GLP-1 and compounded semaglutide products are drawing renewed regulatory scrutiny over risk ...

The National Academies of Sciences, Engineering, and Medicine are private, nonprofit institutions that provide expert advice on some of the most pressing challenges facing the nation and world. Our ...

President Donald Trump’s administration on Tuesday rolled out an executive action aimed at limiting direct-to-consumer advertising for pharmaceuticals, with officials saying a recent Hims & Hers ...

Hims & Hers expands its personalized wellness platform, aiming to reshape preventive care through tech-driven, holistic solutions.

Hims & Hers announces plans to expand its weight loss program to Canada in 2026. Novo Nordisk is set to lose patent protection on Ozempic and Wegovy in Canada next year. Post-Labor Day Trading Could ...

Hims & Hers Health, Inc. is a Strong Buy with rapid revenue growth, solid fundamentals, and 26% projected upside. Click for ...

Hims & Hers Health, Inc. (NYSE:HIMS) is one of the Stocks With Huge Catalysts on the Horizon. On July 9, Hims & Hers Health, Inc. (NYSE:HIMS) announced expanding into Canada with a new affordable ...

Hims & Hers' scalable model, product launches, and global expansion plans support its ambitious 2030 revenue and EBITDA ...

ZAVA served 1.3 million+ customers and delivered 2.3 million consultations across four European countries in 2024. Needham sees $52.1 billion in weight loss market potential in ZAVA’s existing regions ...